# Role and Function of O-GlcNAcylation in Cancer

**Authors:** Jii Bum Lee, Kyoung-Ho Pyo, Hye Ryun Kim

PMC · DOI: 10.3390/cancers13215365 · Cancers · 2021-10-26

## TL;DR

This review explores how O-GlcNAcylation, a metabolic modification, contributes to cancer progression and resistance to treatment, and its potential as a therapeutic target.

## Contribution

The paper provides a comprehensive review of O-GlcNAcylation's role in cancer metabolism, immune response, and chemoresistance.

## Key findings

- O-GlcNAcylation is involved in cancer cell proliferation, metastasis, and resistance to chemotherapy.
- It modulates immune responses in the tumor microenvironment and affects T cell and macrophage activation.
- O-GlcNAcylation inhibitors show potential as therapeutic agents to overcome chemoresistance.

## Abstract

Despite the rapid advancement in immunotherapy and targeted agents, many patients diagnosed with cancer have poor prognosis with dismal overall survival. One of the key hallmarks of cancer is the ability of cancer cells to reprogram their energy metabolism. O-GlcNAcylation is an emerging potential mechanism for cancer cells to induce proliferation and progression of tumor cells and resistance to chemotherapy. This review summarizes the mechanism behind O-GlcNAcylation and discusses the role of O-GlcNAcylation, including its function with receptor tyrosine kinase and chemo-resistance in cancer, and immune response to cancer and as a prognostic factor. Further pre-clinical studies on O-GlcNAcylation are warranted to assess the clinical efficacy of agents targeting O-GlcNAcylation.

Cancer cells are able to reprogram their glucose metabolism and retain energy via glycolysis even under aerobic conditions. They activate the hexosamine biosynthetic pathway (HBP), and the complex interplay of O-linked N-acetylglucosaminylation (O-GlcNAcylation) via deprivation of nutrients or increase in cellular stress results in the proliferation, progression, and metastasis of cancer cells. Notably, cancer is one of the emerging diseases associated with O-GlcNAcylation. In this review, we summarize studies that delineate the role of O-GlcNAcylation in cancer, including its modulation in metastasis, function with receptor tyrosine kinases, and resistance to chemotherapeutic agents, such as cisplatin. In addition, we discuss the function of O-GlcNAcylation in eliciting immune responses associated with immune surveillance in the tumor microenvironment. O-GlcNAcylation is increasingly accepted as one of the key players involved in the activation and differentiation of T cells and macrophages. Finally, we discuss the prognostic role of O-GlcNAcylation and potential therapeutic agents such as O-linked β-N-acetylglucosamine-transferase inhibitors, which may help overcome the resistance mechanism associated with the reprogramming of glucose metabolism.

## Linked entities

- **Chemicals:** cisplatin (PubChem CID 5460033)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, RIPK3 (receptor interacting serine/threonine kinase 3) [NCBI Gene 11035] {aka RIP3}, RIPK1 (receptor interacting serine/threonine kinase 1) [NCBI Gene 8737] {aka AIEFL, IMD57, RIP, RIP-1, RIP1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, HCFC1 (host cell factor C1) [NCBI Gene 3054] {aka CFF, HCF, HCF-1, HCF1, HFC1, MAHCX}, Oga (O-GlcNAcase) [NCBI Gene 76055] {aka Hy5, Mgea5, Ncoat}, LCK (LCK proto-oncogene, Src family tyrosine kinase) [NCBI Gene 3932] {aka IMD22, LSK, YT16, p56lck, pp58lck}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, SIN3A (SIN3 transcription regulator family member A) [NCBI Gene 25942] {aka CHR15DELq24, DEL15Q24, WITKOS}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, REL (REL proto-oncogene, NF-kB subunit) [NCBI Gene 5966] {aka C-Rel, HIVEN86A, IMD92}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, UBE2S (ubiquitin conjugating enzyme E2 S) [NCBI Gene 27338] {aka E2-EPF, E2EPF, EPF5}, TMPRSS11D (transmembrane serine protease 11D) [NCBI Gene 9407] {aka ASP, HAT}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, MAVS (mitochondrial antiviral signaling protein) [NCBI Gene 57506] {aka CARDIF, IPS-1, IPS1, VISA}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, NFATC1 (nuclear factor of activated T cells 1) [NCBI Gene 4772] {aka NF-ATC, NF-ATc1.2, NFAT2, NFATc}, UAP1 (UDP-N-acetylglucosamine pyrophosphorylase 1) [NCBI Gene 6675] {aka AGX, AGX1, AGX2, SPAG2}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, NOD2 (nucleotide binding oligomerization domain containing 2) [NCBI Gene 64127] {aka ACUG, BLAU, BLAUS, CARD15, CD, CLR16.3}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, ERRFI1 (ERBB receptor feedback inhibitor 1) [NCBI Gene 54206] {aka GENE-33, MIG-6, MIG6, RALT}, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) [NCBI Gene 8473] {aka HINCUT-1, HRNT1, MRX106, O-GLCNAC, OGT1, XLID106}, VIM (vimentin) [NCBI Gene 7431], EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, GFPT1 (glutamine--fructose-6-phosphate transaminase 1) [NCBI Gene 2673] {aka CMS12, CMSTA1, GFA, GFAT, GFAT 1, GFAT1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, INPP5D (inositol polyphosphate-5-phosphatase D) [NCBI Gene 3635] {aka SHIP, SHIP-1, SHIP1, SIP-145, hp51CN, p150Ship}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CLEC10A (C-type lectin domain containing 10A) [NCBI Gene 10462] {aka CD301, CLECSF13, CLECSF14, DC-ASGPR, HML, HML2}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, NEFH (neurofilament heavy chain) [NCBI Gene 4744] {aka CMT2CC, NFH}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, ZAP70 (zeta chain of T cell receptor associated protein kinase 70) [NCBI Gene 7535] {aka ADMIO2, IMD48, SRK, STCD, STD, TZK}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, GLYATL1 (glycine-N-acyltransferase like 1) [NCBI Gene 92292] {aka GATF-C, GNAT}, STAT5A (signal transducer and activator of transcription 5A) [NCBI Gene 6776] {aka MGF, STAT5}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, KLF8 (KLF transcription factor 8) [NCBI Gene 11279] {aka BKLF3, ZNF741}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** prostate and colorectal cancers (MESH:D015179), infection (MESH:D007239), neurodegenerative disease (MESH:D019636), lung cancer (MESH:D008175), vesicular stomach virus (MESH:D013272), hyperglycemia (MESH:D006943), hepatocellular carcinoma (MESH:D006528), toxicities (MESH:D064420), diabetic nephropathy (MESH:D003928), Alzheimer disease (MESH:D000544), breast, colorectal, prostate, and hepatocellular carcinoma (MESH:D011472), PDAC (MESH:D021441), squamous cell lung cancer (MESH:D018307), head and neck cancer (MESH:D006258), inflammation (MESH:D007249), adenocarcinoma (MESH:D000230), lung tumorigenesis (MESH:D063646), Metastasis (MESH:D009362), Cancer (MESH:D009369), NSCLC (MESH:D002289), Breast cancers (MESH:D001943), diabetes (MESH:D003920), squamous cell carcinoma of lung (MESH:D002294), II, III, and IV lung adenocarcinomas (MESH:D000077192), cervical cancer (MESH:D002583)
- **Chemicals:** GlcNAc (MESH:D000117), pemetrexed (MESH:D000068437), Hexosamine (MESH:D006595), ATP (MESH:D000255), serine (MESH:D012694), Glucosamine-6-P (-), acetyl-CoA (MESH:D000105), oxaloacetate (MESH:D062907), fructose-6-phosphate (MESH:C027618), oxygen (MESH:D010100), doxorubicin (MESH:D004317), Glucosamine-1-phosphate (MESH:C038515), glucosamine-6-phosphate (MESH:C001293), sugar (MESH:D000073893), amino acid (MESH:D000596), docetaxel (MESH:D000077143), threonine (MESH:D013912), LPS (MESH:D008070), Tricarboxylic acid (MESH:D014233), navelbine (MESH:D000077235), carboplatin (MESH:D016190), tamoxifen (MESH:D013629), phosphatidylinositol-3,4,5-trisphosphate (MESH:C060974), TMG (MESH:D001622), glutamine (MESH:D005973), glucose (MESH:D005947), UDP-N-acetylglucosamine (MESH:D014537), fatty acid (MESH:D005227), cisplatin (MESH:D002945)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Bacteroides thetaiotaomicron (species) [taxon 818], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8582477/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC8582477/full.md

## References

111 references — full list in the complete paper: https://tomesphere.com/paper/PMC8582477/full.md

---
Source: https://tomesphere.com/paper/PMC8582477